Imaging agent for detection of diseased cells
The present invention provides compositions and methods for imaging, for example, tumor resections.
1. A compound of formula I:
or a pharmaceutically acceptable salt thereof,
wherein n is an integer between 400 and 500, inclusive.
2. The compound of claim 1 , wherein n is an integer between 440-460, inclusive.
3. The compound of claim 1 , wherein the portion of the molecule defined by brackets (mPEG portion) is about 20,000 g/mol in molecular weight.
4. The compound of claim 1 , wherein the formula is:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein the compound is provided as an acetate salt.
6. A composition comprising one or more compounds of claim 1 or a pharmaceutically acceptable salt thereof.
7. A composition comprising a plurality of compounds of claim 1 or a pharmaceutically acceptable salt thereof.
8. The composition of claim 7 , wherein the average value of n for the compounds in the composition is between 440-460, inclusive.
9. The composition of claim 7 , wherein the average value of n for the compounds in the composition is about 450.
10. The composition of claim 7 , wherein the average molecular weight of the mPEG portion of the molecules,
is about 20,000 g/mol.
11. A compound of formula II:
or a salt thereof.
12. An in-vivo method for spatially determining tissue heterogeneity of tissue of a subject comprising:
(a) administering a composition of claim 6 to the subject; and
(b) obtaining after said administration step an in-situ image of said tissue.
13. The in-vivo method of claim 12 , wherein the image is obtained using an imaging system having pixels with a field of view, and wherein the field of view of each pixel when said image is obtained is one cell or less than one cell.
14. The method of claim 12 , wherein the composition is administered systemically and the image is obtained between 12 and 72 hours after the composition is administered.
15. The method of claim 12 , wherein the composition is administered systemically and the image is obtained between 12 and 36 hours after administration.
16. The method of claim 12 , wherein the image distinguishes between diseased cells and healthy cells within 5 mm, 4 mm, 3 mm, 2 mm, or even 1 mm from the surface of the tissue.
17. The method of claim 16 , wherein the image does not distinguish between diseased cells and healthy cells that are deeper than 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, or 10 mm from the surface of the tissue.
18. The method of claim 12 , wherein the image distinguishes between diseased cells and healthy cells, and the diseased cell is a cancer cell.
19. The method of claim 12 , wherein the tissue is a tissue bed left behind after tumor resection.
20. The method of claim 12 , wherein the subject is a human.
21. The method of claim 12 , wherein the composition is administered topically in-vivo.